Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Clinical Outcomes and Follow-Up Care in Gynecological Cancers
share announcement

Special Issue "Clinical Outcomes and Follow-Up Care in Gynecological Cancers"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Survivorship and Quality of Life".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 3630

Special Issue Editors

Dr. Esther Louise Moss

E-Mail Website
Guest Editor
Department of Genetics and Genome Biology, Leicester Cancer Research Centre, University of Leicester, Leicester LE1 7RH, UK
Interests: gynecological cancer survivorship and follow-up
Dr. Jo Morrison
E-Mail Website
Guest Editor
Somerset NHS Foundation Trust, Taunton TA1 5DA, UK
Interests: gynecological cancers

Special Issue Information

Dear Colleagues, 

Over the past decade, there has been increasing focus on cancer survivorship and the impact that this may have on patient outcomes. The incidence of gynaecological cancers is changing in many countries and as a result many changes have been proposed for patient follow-up, with a greater emphasis on tailoring follow-up schemes and schedules to patients’ needs. The COVID-19 pandemic accelerated the introduction of virtual follow-up schemes in many countries, for example, telephone or patient-initiated follow-up. Clinical trials to date have mainly focused on the role of such schemes in uterine cancer, although the impact on long-term survival has yet to be determined. In this Special Issue on ‘Clinical Outcomes and Follow-Up Care in Gynecological Cancers’, we aim to cover all aspects of gynaecological cancer follow-up, including patient experiences, clinical outcomes and the impact on healthcare providers. We welcome articles from research to clinical applications. 

Dr. Esther Louise Moss
Dr. Jo Morrison
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cervical cancer
  • ovarian cancer
  • uterine cancer
  • survivorship
  • quality of life
  • patient-initiated follow-up
  • personalised stratified follow-up
  • late effects
  • patient experience

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 563 KiB  
Article
A Novel Score Using Lymphocyte-to-Monocyte Ratio in Blood and Malignant Body Fluid for Predicting Prognosis of Patients with Advanced Ovarian Cancer
by
Min Jin Jeong
,
Yeo Nyeong Yoon
,
Yeon Kyung Kang
,
Chan Joo Kim
,
Hae Seong Nam
and
Yong Seok Lee
Cancers 2023, 15(8), 2328; https://doi.org/10.3390/cancers15082328 - 17 Apr 2023
Viewed by 909
Abstract
(1) Background: The lymphocyte-to-monocyte ratio (LMR), one of the systemic inflammatory markers, has been shown to be associated with prognosis of various solid tumors. However, no study has reported clinical utility of the LMR of malignant body fluid (mLMR) (2) Methods: We retrospectively [...] Read more.
(1) Background: The lymphocyte-to-monocyte ratio (LMR), one of the systemic inflammatory markers, has been shown to be associated with prognosis of various solid tumors. However, no study has reported clinical utility of the LMR of malignant body fluid (mLMR) (2) Methods: We retrospectively analyzed clinical data of the final 92 patients of a total of 197 patients with advanced ovarian cancer newly diagnosed from November 2015 and December 2021 using our institute big data. (3) Results: Patients were divided into three groups according to their combined bLMR and mLMR scores (bmLMR score): 2, both bLMR and mLMR were elevated; 1, bLMR or mLMR was elevated; and 0, neither bLMR nor mLMR was elevated. A multivariable analysis confirmed that the histologic grade (p = 0.001), status of residual disease (p < 0.001), and bmLMR score (p < 0.001) were independent predictors of disease progression. A low combined value of bLMR and mLMR was strongly associated with a poor prognosis in patients with ovarian cancer. (4) Conclusions: Although further studies are required to apply our results clinically, this is the first study to validate the clinical value of mLMR for predicting prognosis of patients with advanced ovarian cancer. Full article
(This article belongs to the Special Issue Clinical Outcomes and Follow-Up Care in Gynecological Cancers)
►▼ Show Figures

Figure 1

Other

Jump to: Research

22 pages, 928 KiB  
Systematic Review
Evaluating the Harms of Cancer Testing—A Systematic Review of the Adverse Psychological Correlates of Testing for Cancer and the Effectiveness of Interventions to Mitigate These
by
Fong Lien Kwong
,
Clare Davenport
and
Sudha Sundar
Cancers 2023, 15(13), 3335; https://doi.org/10.3390/cancers15133335 - 25 Jun 2023
Viewed by 641
Abstract
(1) Background: Several studies have described the psychological harms of testing for cancer. However, most were conducted in asymptomatic subjects and in cancers with a well-established screening programme. We sought to establish cancers in which the literature is deficient, and identify variables associated [...] Read more.
(1) Background: Several studies have described the psychological harms of testing for cancer. However, most were conducted in asymptomatic subjects and in cancers with a well-established screening programme. We sought to establish cancers in which the literature is deficient, and identify variables associated with psychological morbidity and interventions to mitigate their effect. (2) Methods: Electronic bibliographic databases were searched up to December 2020. We included quantitative studies reporting on variables associated with psychological morbidity associated with cancer testing and primary studies describing interventions to mitigate these. (3) Results: Twenty-six studies described individual, testing-related, and organisational variables. Thirteen randomised controlled trials on interventions were included, and these were categorised into five groups, namely the use of information aids, music therapy, the use of real-time videos, patient navigators and one-stop clinics, and pharmacological or homeopathic therapies. (4) Conclusions: The contribution of some factors to anxiety in cancer testing and their specificity of effect remains inconclusive and warrants further research in homogenous populations and testing contexts. Targeting young, unemployed patients with low levels of educational attainment may offer a means to mitigate anxiety. A limited body of research suggests that one-stop clinics and patient navigators may be beneficial in patients attending for diagnostic cancer testing. Full article
(This article belongs to the Special Issue Clinical Outcomes and Follow-Up Care in Gynecological Cancers)
►▼ Show Figures

Figure 1

23 pages, 6528 KiB  
Systematic Review
Impact of Hormone Replacement Therapy on the Overall Survival and Progression Free Survival of Ovarian Cancer Patients: A Systematic Review and Meta-Analysis
by
Patriciu Andrei Achimaș-Cadariu
,
Diana Loreta Păun
and
Andrei Pașca
Cancers 2023, 15(2), 356; https://doi.org/10.3390/cancers15020356 - 05 Jan 2023
Cited by 3 | Viewed by 1577
Abstract
Background: Frequently, patients treated for Ovarian Cancer (OC) undergo menopause with subsequent symptoms. This review scrutinised the impact of Hormone Replacement Therapy (HRT) on the Overall Survival (OS) and Progression-Free Survival (PFS) of patients diagnosed with OC. Methods: A systematic literature search was [...] Read more.
Background: Frequently, patients treated for Ovarian Cancer (OC) undergo menopause with subsequent symptoms. This review scrutinised the impact of Hormone Replacement Therapy (HRT) on the Overall Survival (OS) and Progression-Free Survival (PFS) of patients diagnosed with OC. Methods: A systematic literature search was conducted in the most popular English databases. Inclusion and exclusion criteria were applied to select publications that evaluate OS and PFS in these patients. End-point analysis targeted values of log(HR) and its Standard Error (SE). Results: Up to 1 September 2022, 11 studies were included in the qualitative synthesis. Eight publications, totalling 4191 patients, were included in the meta-analyses. Eight studies were considered for the OS analysis and pooled an HR of 0.66 with respective 95% CI between 0.57 and 0.76, with a p-value < 0.00001 at a Z value of 5.7, in favour of the HRT group. Results for PFS showed an overall HR of 0.73 in favour of the HRT group; CI between 0.57 and 0.95, p = 0.02 at a Z value of 2.36. Further subgroup analyses highlighted the non-inferiority of this treatment. Conclusions: Patients treated for OC that receive HRT for menopausal symptoms after various treatments appeared to have better OS than never-users. Full article
(This article belongs to the Special Issue Clinical Outcomes and Follow-Up Care in Gynecological Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop